Business Context and Reporting Period
Company: Altria Group, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Six and three months ended June 30, 2026
Business Overview: Altria is a leading portfolio of nicotine products for U.S. consumers age 21+, operating primarily through subsidiaries Philip Morris USA (cigarettes), U.S. Smokeless Tobacco Company (moist smokeless tobacco), Helix Innovations (oral nicotine pouches), and NJOY (e-vapor). The company also holds significant equity investments in Anheuser-Busch InBev (ABI) and Cronos Group Inc.
Key Financial Metrics
| Metric (in millions, except per share) | Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
Three Months Ended June 30, 2026 |
Three Months Ended June 30, 2025 |
|---|---|---|---|---|
| Net Revenues | $11,539 | $11,361 | $6,111 | $6,102 |
| Operating Income | $6,092 | $5,018 | $3,136 | $3,230 |
| Net Earnings | $4,481 | $3,455 | $2,298 | $2,378 |
| Diluted EPS | $2.67 | $2.04 | $1.37 | $1.41 |
| Operating Cash Flow | $3,043 | $2,925 | N/A | N/A |
| Total Debt (Carrying Value) | $24,577 | $25,709 | N/A | N/A |
| Cash and Cash Equivalents | $2,367 | $4,474 | N/A | N/A |
| Debt-to-Consolidated EBITDA | 1.9x | N/A | N/A | N/A |
Note: Debt-to-Consolidated EBITDA is calculated for the twelve months ended June 30, 2026.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 1.6% year-over-year for the six months ended June 30, 2026, driven primarily by higher pricing in the smokeable products segment, partially offset by lower shipment volumes.
- Profitability: Net earnings increased 29.7% to $4.481 billion for the six-month period. This significant increase is largely attributable to the absence of a $873 million non-cash goodwill impairment charge recorded in the e-vapor reporting unit during the first quarter of 2025.
- Segment Performance:
- Smokeable Products: Operating Companies Income (OCI) increased 4.0% due to higher pricing and tax refunds, despite a 2.8% decline in domestic cigarette shipment volume.
- Oral Tobacco Products: OCI decreased 12.4% due to lower shipment volumes (down 6.0%) and $78 million in pre-tax exit costs related to the USSTC Facilities Consolidation.
- Investment Income: (Income) losses from investments in equity securities improved by $46 million year-over-year, though still negatively impacted by ABI-related special items (dilution losses).
- Liquidity: Cash and cash equivalents decreased by approximately $2.1 billion from the beginning of the period, primarily due to dividend payments ($3.556 billion) and share repurchases ($335 million).
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items:
- Exit Costs: The company incurred $78 million in pre-tax exit and implementation costs for the six months ended June 30, 2026, primarily related to consolidating USSTC manufacturing facilities in Tennessee to Kentucky.
- ABI Dilution: Recorded net pre-tax losses of $78 million related to ABI share activity reducing ownership interest.
- Goodwill Impairment: No impairment charges were recorded in 2026, contrasting with the $873 million charge in Q1 2025 following the ITC exclusion order on NJOY ACE.
- Outlook and Guidance:
- Capital Expenditures: Expected to range between $375 million and $450 million for 2026, an increase from the prior year range, driven by the USSTC consolidation.
- Dividends: Current annualized dividend rate is $4.24 per share, with a goal of mid-single-digit annual growth through 2028.
- Share Repurchases: $665 million remaining under the current program, which expires December 31, 2026.
- Risks and Contingencies:
- Regulatory: Ongoing FDA enforcement actions against illicit e-vapor products and potential product standards (e.g., nicotine reduction in cigarettes, flavor bans) pose significant risks.
- Litigation: Significant exposure remains regarding tobacco and health litigation, including Engle progeny cases and patent infringement suits involving NJOY products (e.g., NJOY Daily vs. JUUL).
- Market Dynamics: Continued decline in cigarette volumes due to consumer shift to discount brands and illicit disposable e-vapor products.
Key Facts for Investor Verification
- Volume Decline: Verify the sustainability of revenue growth given the 2.8% year-over-year decline in domestic cigarette shipment volumes and the 6.0% decline in oral tobacco volumes.
- One-Time Impacts: Confirm the extent to which the 29.7% net earnings increase is driven by the absence of the 2025 goodwill impairment rather than operational improvements.
- Exit Costs: Monitor the execution and total cost of the USSTC Facilities Consolidation, estimated at $180 million total pre-tax charges.
- Regulatory Status: Track the status of the ITC exclusion order on NJOY ACE and the ongoing patent litigation regarding NJOY Daily, which could impact the e-vapor segment's future viability.
- ABI Investment: Assess the impact of continued dilution losses on the ABI investment and the fair value gap (fair value exceeded carrying value by 54% as of June 30, 2026).